Trends in transfusion burden among long-term survivors of childhood hematological malignancies

Leukemia and Lymphoma

Volumn 54, Issue 8, 2013, Pages 1719-1723

  Nottage, Kerri ^a   Gurney, James G ^a   Smeltzer, Matthew ^a   Castellanos, Maria ^a   Hudson, Melissa M ^a   Hankins, Jane S ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Cancer survivors; Iron overload; Pediatric leukemia; Transfusion medicine

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BODY BURDEN; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CANCER SURVIVOR; CHILD; CHILDHOOD CANCER; ERYTHROCYTE TRANSFUSION; FEMALE; GRAFT RECIPIENT; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; IRON OVERLOAD; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRESCHOOL CHILD; PRIORITY JOURNAL; RATING SCALE; SCHOOL CHILD; TREATMENT RATING SCALE 3; TREND STUDY;

ADOLESCENT; ADULT; BLOOD TRANSFUSION; CHILD; CHILD, PRESCHOOL; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; INFANT, NEWBORN; IRON OVERLOAD; MALE; SURVIVORS; YOUNG ADULT;

EID: 84880274343     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.750724     Document Type: Article

References (31)

1. Jemal A, Siegel R, Xu J, et a l. Cancer statistics, 2 010. C A Cancer J Clin 2010; 60 : 277-300
2. Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual diseasedirected therapy for childhood acute myeloid leukaemia: Results of the AML02 multicentre trial. Lancet Oncol 2010 ; 11 : 543-552
3. Creutzig U, Zimmermann M, Lehrnbecher T, et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents withacute myeloid leukemia: Results of AML-BFM 98. J Clin Oncol 2006 ; 24 : 4499-4506
4. Lehrnbecher T, Zimmermann M, Reinhardt D, et a l. Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia. Blood 2007 ; 109 : 936-943
5. Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. NEngl J Med 2009 ; 360 : 2730-2741
6. Schmiegelow K, Forestier E, Hellebostad M, et al. Long-Term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia 2010; 24: 345-354
7. Olivieri NF. Progression of iron overload in sickle cell disease. Semin Hematol 2001 ; 38 : 57-62
8. Inati A, Musallam KM, Wood JC, et al. Iron overload indices rise linearly with transfusion rate in patients with sickle cell disease. Blood 2010 ; 115 : 2980-2981 ; author reply 2981-2982
9. Anderson L, Holden S, Davis B, et a l. Cardiovascular T2-star (T2) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001 ; 22 : 2171-2179
10. Thakerngpol K, Fucharoen S, Boonyaphipat P, et al. Liver injury due to iron overload in thalassemia: Histopathologic and ultrastructural studies. Biometals 1996 ; 9 : 177-183
11. Risdon R, Barry M, Flynn D. Transfusional iron overload: The relationship between tissue iron concentration and hepatic fi brosis in thalassaemia. JPathol 1975 ; 116 : 83-95
12. Olivieri N, Nathan D, MacMillan J, et al. Survival in medically treated patients with homozygous beta-Thalassemia. NEngl J Med 1994 ; 331 : 574-578
13. Zurlo M, De Stefano P, Borgna-Pignatti C, et al. Survival and causes of death in thalassaemia major. Lancet 1989; 2: 27-30
14. Merkel PA, Simonson DC, Amiel SA, et al. Insulin resistance and hyperinsulinemia in patients with thalassemia major treated by hypertransfusion. NEngl J Med 1988; 318: 809-814
15. Kazak AE, Hocking MC, Ittenbach RF, et al. Arevision of the intensity of treatment rating scale: Classifying the intensity of pediatric cancer treatment. Pediatr Blood Cancer 2012 ; 59 : 96-99
16. Eng J, Fish JD. Insidious iron burden in pediatric patients withacute lymphoblastic leukemia. Pediatr Blood Cancer 2011; 56: 368-371
17. Ruccione KS, Mudambi K, Sposto R, et al. Association of projected transfusional iron burden with treatment intensity in childhood cancer survivors. Pediatr Blood Cancer 2012 ; 59 : 697-702
18. Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2009. Bethesda, MD: National Cancer Institute; 2012
19. Ness KK, Armenian SH, Kadan-Lottick N, et al. Adverse effects of treatment in childhood acute lymphoblastic leukemia: General overview and implications for long-Term cardiac health. Expert Rev Hematol 2011 ; 4 : 185-197
20. Mody R, Li S, Dover DC, et al. Twenty-fi ve-year follow-up among survivors of childhood acute lymphoblastic leukemia: A report from the Childhood Cancer Survivor Study. Blood 2008; 111: 5515-5523
21. Armstrong G T, Liu Q, Yasui Y, et a l. Late mortality among 5-year survivors of childhood cancer: A summary from the Childhood Cancer Survivor Study. J Clin Oncol 2009; 27: 2328-2338
22. Kurt B A, Nolan V G, Ness K K, et a l. Hospitalization rates among survivors of childhood cancer in the Childhood Cancer Survivor Study cohort. Pediatr Blood Cancer 2012 ; 59 : 126-132
23. Gurney J, Ness K, Sibley S, et al. Metabolic syndrome and growth hormone deficiency in adult survivors of childhood acute lymphoblastic leukemia. Cancer 2006; 107: 1303-1312
24. Link K, Mo ë ll C, Garwicz S, et al. Growth hormone deficiency predicts cardiovascular risk in young adults treated for acute lymphoblastic leukemia in childhood. J Clin Endocrinol Metab 2004; 89: 5003-5012
25. Taskinen M, Saarinen-Pihkala U, Hovi L, et al. Impaired glucose tolerance and dyslipidaemia as late effects after bone-marrow transplantation in childhood. Lancet 2000 ; 356 : 993-997
26. Sheth S. SQUID biosusceptometry in the measurement of hepatic iron. Pediatr Radiol 2003; 33: 373-377
27. Fischer R, Piga A, Harmatz P, et a l. Monitoring long-Term Efficacy of iron chelation treatment with biomagnetic liver susceptometry. Ann NY Acad Sci 2005 ; 1054 : 350-357
28. Nielsen P, Engelhardt R, Düllmann J, et al. Non-invasive liver iron quantifi cation by SQUID-biosusceptometry and serum ferritin iron as new diagnostic parameters in hereditary hemochromatosis. Blood Cells Mol Dis 2002 ; 29 : 451-458
29. St Pierre T G, Clark P R, Chua-Anusorn W, et a l. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005 ; 105 : 855-861
30. Wood JC, Enriquez C, Ghugre N, et al. MRI R2 and R2. mapping accurately estimates hepatic iron concentration in transfusiondependent thalassemia and sickle cell disease patients. Blood 2005 ; 106 : 1460-1465
31. Hankins JS, McCarville MB, Loeffler RB, et al. R2 . magnetic resonance imaging of the liver in patients with iron overload. Blood 2009 ; 113 : 4853-4855